Literature DB >> 12538087

Bimatoprost (Lumigan((R))) is an agonist at the cloned human ocular FP prostaglandin receptor: real-time FLIPR-based intracellular Ca(2+) mobilization studies.

N A Sharif1, C R Kelly, G W Williams.   

Abstract

Bimatoprost is the ethyl amide derivative of 17-phenyl-trinor prostaglandin F(2alpha). Here, we show that bimatoprost (K(i)=9250+/-846nM) and bimatoprost free acid (17-phenyl-trinor prostaglandin F(2alpha); K(i)=59+/-6nM) bind to the FP receptor and displace [(3)H]-travoprost acid, a selective FP agonist. Bimatoprost (EC(50)=3070+/-1330nM), Lumigan((R)) (bimatoprost 0.03% ophthalmic solution; EC(50)=1150+/-93nM) and bimatoprost acid (EC(50)=15+/-3nM) mobilized intracellular Ca(2+) ([Ca(2+)](i)) in <5s in HEK-293 cells expressing the cloned human ciliary body FP receptor on a fluorometric imaging plate reader (FLIPR). Furthermore, agonist effects of bimatoprost and bimatoprost acid were blocked by AL-8810 (11beta-fluoro-15-epi-15-indanyl prostaglandin F(2alpha); K(i)=0.7-2.1 MicroM), an FP receptor-selective antagonist. Therefore, the prodrug bimatoprost and its hydrolytic product, bimatoprost free acid, bind to and activate the human ocular FP prostaglandin receptor to mobilize [Ca(2+)](i), thus behaving as FP receptor agonists.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538087     DOI: 10.1016/s0952-3278(02)00232-6

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  10 in total

1.  Cellular basis for bimatoprost effects on human conventional outflow.

Authors:  W Daniel Stamer; David Piwnica; Thierry Jolas; Robert W Carling; Clive L Cornell; Hans Fliri; Jose Martos; Simon N Pettit; Jenny W Wang; David F Woodward
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-30       Impact factor: 4.799

2.  Discovery to Launch of Anti-allergy (Emadine; Patanol/Pataday/Pazeo) and Anti-glaucoma (Travatan; Simbrinza) Ocular Drugs, and Generation of Novel Pharmacological Tools Such as AL-8810.

Authors:  Najam A Sharif
Journal:  ACS Pharmacol Transl Sci       Date:  2020-11-05

3.  Comparison of the effects of bimatoprost and timolol on intraocular pressure and pulsatile ocular blood flow in patients with primary open-angle glaucoma: A prospective, open-label, randomized, two-arm, parallel-group study.

Authors:  Michele Vetrugno; Nicola Cardascia; Francesco Cantatore; Carlo Sborgia
Journal:  Curr Ther Res Clin Exp       Date:  2004-11

Review 4.  Prostaglandin FP receptor antagonists: discovery, pharmacological characterization and therapeutic utility.

Authors:  Najam A Sharif; Peter G Klimko
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

5.  Studies using isolated uterine and other preparations show bimatoprost and prostanoid FP agonists have different activity profiles.

Authors:  June Chen; Judith Senior; Kay Marshall; Farhat Abbas; Helen Dinh; Tim Dinh; Larry Wheeler; David Woodward
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

6.  Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.

Authors:  Aswani Dutt Vadlapudi; Ashaben Patel; Kishore Cholkar; Ashim K Mitra
Journal:  Recent Pat Biomed Eng       Date:  2012-04-01

7.  Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients.

Authors:  M Figus; M Nardi; P Piaggi; M Sartini; G Guidi; L Martini; S Lazzeri
Journal:  Eye (Lond)       Date:  2014-01-17       Impact factor: 3.775

8.  In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%.

Authors:  Abayomi B Ogundele; David Earnest; Marsha A McLaughlin
Journal:  Clin Ophthalmol       Date:  2010-07-30

Review 9.  Prostamides (prostaglandin-ethanolamides) and their pharmacology.

Authors:  D F Woodward; Y Liang; A H-P Krauss
Journal:  Br J Pharmacol       Date:  2007-08-27       Impact factor: 8.739

Review 10.  Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.

Authors:  Rohan Bir Singh; Lingjia Liu; Ann Yung; Sonia Anchouche; Sharad K Mittal; Tomas Blanco; Thomas H Dohlman; Jia Yin; Reza Dana
Journal:  Ocul Surf       Date:  2021-05-15       Impact factor: 6.268

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.